Поставка лекарственного препарата для медицинского применения Блинатумомаб

This tender, originating from Russia and managed through the state procurement system (gosplan_ru), concerns the supply of the medicinal product Blinatumomab. Blinatumomab is a bispecific T-cell engager immunotherapy used in the treatment of certain types of acute lymphoblastic leukemia (ALL). The procurement aims to secure a supply of this critical therapeutic agent for use within the Russian healthcare sector. As a state procurement, it is expected that bidders must meet rigorous quality and regulatory requirements, including adherence to pharmaceutical Good Manufacturing Practice (GMP) and all applicable Russian Federation laws governing medicinal products. Potential suppliers should be authorized distributors or manufacturers with the capacity to deliver the specified drug in its approved formulations. The tender documentation will likely detail the required quantities, specifications, packaging, delivery schedules, and any specific storage and handling instructions necessary for maintaining the drug's efficacy. Compliance with national drug registration and pharmacovigilance requirements will also be essential. This procurement is crucial for providing advanced oncological treatments to patients in Russia.